NO20061018L - Nytt preparat - Google Patents

Nytt preparat

Info

Publication number
NO20061018L
NO20061018L NO20061018A NO20061018A NO20061018L NO 20061018 L NO20061018 L NO 20061018L NO 20061018 A NO20061018 A NO 20061018A NO 20061018 A NO20061018 A NO 20061018A NO 20061018 L NO20061018 L NO 20061018L
Authority
NO
Norway
Prior art keywords
dosage form
composition
pharmaceutically acceptable
drug
release
Prior art date
Application number
NO20061018A
Other languages
English (en)
Norwegian (no)
Inventor
Vincenzo Re
Luigi Martini
John Francis Hoke
Mark Edward Sale
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061018(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20061018L publication Critical patent/NO20061018L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061018A 2003-08-07 2006-03-01 Nytt preparat NO20061018L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49338803P 2003-08-07 2003-08-07
PCT/EP2004/008843 WO2005013935A2 (fr) 2003-08-07 2004-08-06 Nouvelle composition

Publications (1)

Publication Number Publication Date
NO20061018L true NO20061018L (no) 2006-03-01

Family

ID=34135242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061018A NO20061018L (no) 2003-08-07 2006-03-01 Nytt preparat

Country Status (25)

Country Link
US (1) US20070134326A1 (fr)
EP (1) EP1660049A2 (fr)
JP (1) JP2007501773A (fr)
KR (1) KR20060113650A (fr)
CN (2) CN1832729A (fr)
AP (1) AP2006003488A0 (fr)
AR (1) AR045330A1 (fr)
AU (1) AU2004262926B2 (fr)
BR (1) BRPI0413374A (fr)
CA (1) CA2534546A1 (fr)
EA (2) EA011508B1 (fr)
EC (1) ECSP066318A (fr)
IL (1) IL173176A0 (fr)
IS (1) IS8336A (fr)
MA (1) MA27980A1 (fr)
MX (1) MXPA06001407A (fr)
NO (1) NO20061018L (fr)
NZ (1) NZ544696A (fr)
OA (1) OA13230A (fr)
PE (1) PE20050335A1 (fr)
SG (1) SG145717A1 (fr)
TW (1) TW200517127A (fr)
UY (1) UY28457A1 (fr)
WO (1) WO2005013935A2 (fr)
ZA (1) ZA200600521B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1686967A4 (fr) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
GB0502479D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
CN103948557A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
WO2001082867A2 (fr) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. Formulation de noyaux
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada

Also Published As

Publication number Publication date
WO2005013935A3 (fr) 2005-07-14
JP2007501773A (ja) 2007-02-01
TW200517127A (en) 2005-06-01
EP1660049A2 (fr) 2006-05-31
IS8336A (is) 2006-03-02
UY28457A1 (es) 2005-03-31
AR045330A1 (es) 2005-10-26
AU2004262926B2 (en) 2009-11-19
ZA200600521B (en) 2007-01-31
EA011508B1 (ru) 2009-04-28
EA200701409A1 (ru) 2007-10-26
NZ544696A (en) 2009-03-31
CN101239047A (zh) 2008-08-13
US20070134326A1 (en) 2007-06-14
ECSP066318A (es) 2006-07-28
CN1832729A (zh) 2006-09-13
MXPA06001407A (es) 2006-05-15
BRPI0413374A (pt) 2006-10-17
AU2004262926A1 (en) 2005-02-17
IL173176A0 (en) 2006-06-11
PE20050335A1 (es) 2005-06-01
EA200600377A1 (ru) 2006-08-25
AP2006003488A0 (en) 2006-02-28
SG145717A1 (en) 2008-09-29
MA27980A1 (fr) 2006-07-03
WO2005013935A2 (fr) 2005-02-17
OA13230A (en) 2006-12-13
KR20060113650A (ko) 2006-11-02
CA2534546A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20085078L (no) Nye forbindelser
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
GEP20043324B (en) Purine Derivatives
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
WO2005065185A3 (fr) Formulations thermostables et methodes de mise au point desdites formulations
SE0104341D0 (sv) New use
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
DE602004011966D1 (en) Heterocyclylverbindungen
NO20061018L (no) Nytt preparat
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP2097085A2 (fr) Matériaux et procédés thérapeutiques
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
DE60309324D1 (de) Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen
NO20060313L (no) Saquinavirmesylat oral doseringsform
CA2125490C (fr) Agent antimetastatique pour le traitement des tumeurs malignes
RU2002107421A (ru) Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способы их применения
SE0301371D0 (sv) New Compounds
EE05300B1 (et) Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application